Accordingly, IV iron therapy associated with ESAs, emerging hepcidin antagonists, and other emerging ESA agents will each provide important new tools for pharmacologic alternatives in the management of anemia of inflammation in the elderly. This evidence concerns the gene HAMP and anemia.